US · Healthcare · Biotechnology
EPS came in at 4.47 against a street estimate of 4.31 — a beat of 3.8%.
Analysts rate Vertex Pharmaceuticals Inc a buy (18 buy, 14 hold, 2 sell out of 34) with an average price target of $557.12.
| Fund | Stake |
|---|---|
| Capital World Investors | 10.00% |
| BlackRock Inc | 9.44% |
| Capital Research Global Investors | 8.32% |
| Vanguard Capital Management, LLC | 6.51% |
| State Street Corp | 4.62% |
| Amvescap Plc. | 3.11% |
| JPMorgan Chase & Co | 2.77% |
| Geode Capital Management, LLC | 2.42% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 | 2026-07-07 |
| Board / officer change · Q2 2026 | 2026-05-13 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-04 |
| Board / officer change · Q2 2026 | 2026-04-29 |
| Proxy statement · Q2 2026 | 2026-04-02 |
| Annual report FY2025 | 2026-02-13 |
| Quarterly report · Q3 2025 | 2025-11-04 |
Readable in the app.
| Announcement | Date |
|---|---|
| Execution of merger agreement announced between company and parent On July 6, 2026, a company announced it signed a Merger Agreement to be acquired by a parent company. The deal targets significant revenue growth, with expectations of over $5 billion in ann | 2026-07-07 |
| 2026 revenue guidance provided; full year revenue expected $12.95-$13.1 billion Vertex Pharmaceuticals reported strong 2025 financial results with full-year revenue of $12.0 billion, up 9% year-over-year. Fourth quarter revenue reached $3.19 billion, representing 10% gr | 2026-02-12 |
| Refined full year 2025 revenue and expense guidance based on Q3 results Vertex Pharmaceuticals reported strong Q3 2025 results with total revenue of $3.08 billion, up 11% year-over-year, driven by its cystic fibrosis (CF) drugs and new product launches including | 2025-11-03 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Vertex Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.